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Penicillamine kinetics in normal subjects 
The kinetic characteristics of penicillamine are reported in four fasting subjects after four oral 
doses each. On later test days, two of the subjects received an additional single dose 30 min 
after a large breakfast. One subject originally included in the study had to drop out because of 
gastrointestinal disturbances following each of two single doses of penicillamine. The fasting 
plasma levels of penicillamine observed in this study displayed an unusual double peak in the 
plasma levels after single doses. Individual subjects had consistent plasma level patterns for 
each of the four single doses but there was marked intersubject variability in patterns and 
kinetic parameters. The half-life of unchanged penicillamine ranged from 1.66 to 3.15 hr and 
the apparent plasma clearance ranged from 530 to 2300 ml/mm. The administration of 
penicillamine following a large breakfast caused a reduction in the area under the penicillamine 
plasma concentration-time curve corresponding to a decrease in the extent of absorption of 
unchanged penicillamine. 
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Penicillamine has been in use for a number of 
years; in 1954 Walshe26 first introduced it for 
the treatment of Wilson's disease. More recent 
studies of its therapeutic activitiess " have 
shown that penicillamine is effective in the 
treatment of rheumatoid arthritis, which has 
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greatly increased the use of, and research inter- 
est in, this compound. Throughout the several 
decades of the drug's use kinetic studies in man 
have been lacking, primarily because a specific 
and sensitive assay was not available. The de- 
velopment of suitable assay methodology has 
been hampered by the chemical similarity of the 
drug to a number of endogenous compounds, 
and a specific assay is essential for any drug to 
accurately define its kinetic characteristics. 
Many very sensitive analytic methodologies 
that have been developed for penicillamine 
(such as colorimetry, gas chromatography, and 
radioimmunoassay) are not useful for kinetic 
studies because of possible interference from 
endogenous compounds or penicillamine me- 
tabolites. 
To avoid analytic problems previous kinetic 
studies of this drug have been done in ani- 
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Fig. 1. Penicillamine plasma concentration levels 
after oral doses of 250 (.), 500 (A), 750 (A), and 
1,000 mg (*) of the drug to fasting patient P. B. 
nrials12, 13, 15, 18-20 and man6' 16' 27 with radiola- 
beled penicillamine, but the results of these stud- 
ies are inappropriate to describe the kinetics of 
unchanged drug; the levels measured represent 
both parent compound and metabolic products of 
penicillamine as described by Perrett." 
The development of a high-performance liq- 
uid chromatographic (HPLC) method for the de- 
termination of penicillamine21 has provided an 
assay method with the specificity and sensitivity 
necessary to conduct kinetic studies of the un- 
changed drug. We have modified this method 
and adapted it for our use.2 
The study of unchanged penicillamine kinet- 
ics is further complicated by the rapid changes 
that have been shown to occur in the concentra- 
tions of the drug when it is placed in the pres- 
ence of proteinaceous material (including whole 
blood, plasma, and albumin solutions).' An ac- 
curate representation of the concentration of un- 
changed penicillamine in these biological fluids 
is obtained only by rapidly processing each 
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Fig. 2. Penicillamine plasma concentration levels 
after oral doses of 250 (.), 500 (e), 750 (A), and 
1,000 mg (*) of the drug to fasting patient M. V. 
sample' and so these procedures were used for 
the studies we report here. 
We have reported on the kinetic characteris- 
tics of unchanged penicillamine in a female 
mongrel dog when the drug was injected as an 
intravenous bolus dose, as a constant-rate intra- 
venous infusion, and in oral dose form. In this 
report we present the results of a kinetic study 
of penicillamine in five normal subjects. Four 
oral doses were given to each and the effect of 
food on the absorption efficiency of unchanged 
penicillamine were recorded. 
Methods 
Subjects. The kinetics of penicillamine were 
studied in five normal adult male and female 
subjects who were selected from respondents to 
an advertisement based on established criterion, 
namely, an assessment of the subject's avail- 
ability and reliability, physical examination and 
medical history of the subject, and the results of 
hematologic, chemical, and urine analyses. The 






Fig. 3. Area under the penicillamine plasma concen- 
tration-time curve vs. drug dose after oral doses of 
250, 750, and 1,000 mg to the four fasting subjects 
R. B. (.), M. V. (4,), C. M. (A), and R. R. (*). 
subjects were not accepted for participation if 
they were taking any other medications and they 
were instructed not to use any other medications 
for its duration. A differential white blood cell 
count, urine analyses, and a pregnancy test (for 
the women) were also completed before each 
dose of penicillamine on the day preceding the 
study date. The results of these tests were re- 
viewed for signs of drug toxicity and abnormal- 
ities before the subjects were approved for the 
administration of the next dose of penicillamine. 
Individual test results that were outside the lab- 
oratory's normal range were repeated and these 
values were always within the normal range. 
Kinetic study protocol. Each subject that 
completed the single-dose fasting study also re- 
ceived four sequentially larger doses of penicil- 
lamine (250, 500, 750, and 1,000 mg) at 2-wk 
intervals. A fifth dose (750 mg) was adminis- 
tered as an oral solution to one subject (R. B.) 
approximately a month and a half after the 
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largest sequential dose. Several months after the 
completion of the fasting single-dose studies, 
subjects R. B. and C. M. also received addi- 
tional single doses (750 mg) 30 to 40 min after a 
large breakfast. Subject D. F. was dropped 
from the four-dose fasting study after two single 
doses because of nausea and headaches. 
The best experimental design for a study 
constructed to test the effects of dose on the 
kinetics of a drug is the randomized crossover 
design. However, the sequentially incremented 
dose was chosen instead; if manifestations of 
drug toxicity or adverse reactions were detected 
in any of the subjects they would have occurred 
at the lowest possible dose. 
The doses of penicillamine were taken at ap- 
proximately 8 A. M. after an overnight fast. No 
food or beverages (except water) were permit- 
ted after 9:30 P.M. on the day preceding the 
study. For the fasting studies no food or bever- 
ages (except water) were permitted until 4 hr 
after the test dose of penicillamine. For the two 
doses taken after a large breakfast, the subjects 
were given the drug 30 to 40 min after two 
eggs, toast, orange juice, and coffee. 
The doses were administered as multiples of 
125-mg D-penicillamine capsules (Cuprimine) 
in all cases except the one oral solution dose 
given to subject R. B. This dose was adminis- 
tered through a nasogastric tube as a 50 mg/ml 
solution of D-penicillamine. Each dose was 
taken with a minimum of 250 ml of water. 
Samples and assay procedure. Accurately 
timed blood samples were obtained from each 
subject at 0, 20, 40, 60, 80, 120, 150, 180, 
240, 300, 360, 420, and 480 min after penicil- 
lamine. Additional hourly samples for up to 12 
hr after drug were collected for the higher 
doses. 
Blood samples were collected using a heparin 
lock that was inserted into the cephalic vein of 
each subject prior to the start of the study. 
Using a 3-ml syringe, approximately 1 to 3 ml 
blood was drawn through the heparin lock and 
discarded to clear the cannula so it could be 
filled with fresh undiluted blood. A 5-ml blood 
sample was then drawn using a syringe that con- 
tained a small amount of heparin (approxi- 
mately 50 to 100 l of 1,000 U/ml heparin). 
Between each blood sample the heparin lock 
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Fig. 4. Penicillamine plasma (A), whole blood (A), 
and packed cell concentrations (A) after oral doses of 
750 mg (capsules) to fasting subject R. B. 
was flushed and filled with 0.5 to 3 ml sterile 
heparinized bacteriostatic sodium chloride in- 
jection, USP (1,000 U of heparin/30 ml with 
methyl and propyl paraben preservatives), to 
prevent the cannula from becoming clotted. Oc- 
casionally, however, the heparin locks were not 
functional and samples were obtained by direct 
venipuncture with 5-ml heparinized syringes. 
The blood samples were rapidly separated 
into plasma and packed cell components by cen- 
trifugation (Eppindorf microcentrifuge model 
5412, Brinkman Instruments) at 15,000 rpm for 
30 to 45 sec. The plasma was decanted and 
quickly processed by the methods outlined in 
previous publications" 2 to produce the protein- 
free, acidified plasma supernatant in which 
penicillamine is stable. The supernatant samples 
were immediately refrigerated and the penicil- 
lamine content of each sample was determined 
(within 1 to 5 days after collection of the sam- 
ples) by an HPLC electrochemical method.3 
For subject R. B. each blood sample was di- 
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Fig. 5. Penicillamine plasma concentrations after 
750-mg doses as capsules (A) and in solution to fast- 
ing subjects (A) and as capsules after food (A). 
vided into two parts, the first part being treated 
as a whole blood sample by completing a hemo- 
lysis and protein precipitation procedure as de- 
scribed previously.3 The second part of each 
sample was rapidly centrifuged into plasma and 
packed cell components as described above for 
the other subjects. Both of the plasma and 
packed cell fractions were processed as outlined 
in previous publications' to produce stable su- 
pernatant samples. Therefore, in this subject 
alone, all three fractions (whole blood, plasma, 
and packed cell supernatants) were analyzed for 
their penicillamine content by the HPLC elec- 
trochemical method. 
Total voided urine samples were collected for 
each subject over the intervals of 0 to 2, 2 to 4, 
4 to 6, 6 to 8, 8 to 10, and 10 to 12 hr after the 
dose of penicillamine. In a few treatments, 
however, the 8- to 10- or the 10- to 12-hr sam- 
ples, or both, were lost or omitted. The volume 
of each sample was accurately determined and 
recorded. A suitable aliquot of urine was diluted 
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Table I. Kinetic parameters calculated from the observed plasma concentrations 
of penicillamine in five normal subjects 
using 0.4M citric acid solution and the diluted, 
acidified urine specimens were immediately re- 
frigerated. The penicillamine content of the 
urine samples was determined within 1 to 5 
days by the HPLC electrochemical method. 
Pharmacokinetic methods. The pharmaco- 
kinetic methods used are described in the foot- 
notes to Tables I, II, and III. 
Results 
Penicillamine plasma levels. The plasma 
concentrations after the fasting oral administra- 
tion of 250, 500, 750, and 1,000 mg of penicil- 
lamine as a capsule or in solution dosage form 
displayed atypical double peaks for the concen- 
tration-time profiles in all subjects studied. The 
fasting plasma concentrations for two of the 
Clin. Pharmacol. Ther. 
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AUC was calculated from the trapezoidal rule and extrapolated to infinite time using the elimination rate constant and the last plasma concen- 
tration data point. 
Elimination rate constant for the disappearance of penicillamine from plasma was calculated by linear regression of the log-linear terminal 
plasma concentration data. 
Cl/FF* = Clearance divided by absorbed fraction times fraction undergoing first-pass metabolism. 
Apparent plasma clearance was calculated from the ratio of the dose to the AUC. 
*Data in parenthesis are percentages of total AUC that were extrapolated to infinite time. 
tThis oral dose was administered as a solution via nasogastric tube. All other doses were administered as capsules. 
tThese oral doses were administered 30 min after a large breakfast. All other doses were taken in fasting state. 
subjects who received all four doses of penicil- 
lamine are shown in Figs. 1 and 2. 
There were marked differences in the 
concentration-time profiles for the different 
subjects. The results shown in Figs. 1 and 2 
are representative of the extremes observed 
for the subjects. As demonstrated in Figs. 1 and 
2, the fasting plasma concentration-time pro- 
files within the same subject were remarkably 
similar, exhibiting the double peaks at ap- 
proximately the same time after each dose of 
pen icillami ne . 
The relationship of the area under the penicil- 
lamine concentration-time curve (AUC) to the 
dose of penicillamine for the four doses in sub- 
jects who completed the fasting protocol are 





Dose AUC* constant Half-life ClIFF* 
Subjects (mg) ( pglminlml) (hr-') (hr) (ml/mm) 
R. B. 250 310 (4.3) 0.357 1.94 808 
500 872 (2.9) 0.434 1.59 573 
750 1260 (3.0) 0.295 2.35 593 
750t 1089 (1.7) 0.287 2.41 689 
7501: 559 (12.5) 0.418 1.66 1343 
1000 1690 (3.1) 0.220 3.15 591 
D. F. 250 203 (5.0) 0.505 1.37 1230 
500 264 (3.5) 0.443 1.56 1895 
M. V. 250 461 (6.5) 0.443 1.56 542 
500 810 (4.3) 0.315 2.20 617 
750 1190 (3.4) 0.223 3.11 632 
1000 1890 (4.2) 0.232 2.98 528 
C. M. 250 197 (5.6) 0.469 1.48 1268 
500 779 (3.4) 0.308 2.25 642 
750 887 (2.1) 0.388 1.78 846 
7501: 331 (9.7) 0.397 1.75 2266 
1000 1320 (3.5) 0.330 2.10 758 
R. R. 250 107 (16.4) 0.222 3.11 2343 
500 599 (2.4) 0.360 1.92 834 
750 1090 (2.0) 0.312 2.22 689 
1000 1104 (2.2) 0.318 2.18 906 
Table II. Kinetic parameters calculated from the observed urine levels of penicillamine 
for five normal subjects 
Renal clearance was calculated from the ratio Ae./AUCo_. 
*Amount in urine was extrapolated to infinite time using the method of Wagner and Ayres.2' 
tPercentage of dose that was ultimately excreted in urine. 
tOral dose administered as a solution via nasogastric tube; others were as capsules. 
§These oral doses were administered 30 min after a large breakfast; others were administered in fasting state. 
was obtained by a linear regression of the data 
through the origin. The slope of the line is 
0.0931 min * kg/m' (+ / -0.006, r2 = 0.735), 
which corresponds to an average plasma clear- 
ance of 10.7 ml/min/kg or 749 ml/min for a 
70-kg man. 
The plasma penicillamine concentrations for 
subject D. F., who developed nausea and 
headaches after each dose of penicillamine that 
he received, were significantly lower than the 
plasma levels of penicillamine in any of the 
other subjects. Although this subject experi- 
enced nausea, no episodes of emesis occurred 
during the 8 to 10 hr of the study. The decreased 
penicillamine plasma levels for this subject, 
however, show that the gastric distress dramati- 
cally affected the plasma levels. The decreased 
plasma levels are probably due to malabsorption 
of the dose of penicillamine but the exact cause 
of the nausea and the poor absorption of penicil- 
lamine are not clear. The responses may be at- 
tributable to the usual adverse effects associated 
with use of the drug. 
The plasma, whole blood, and packed cell 
concentration levels of penicillamine after the 
750-mg dose administered (in capsules) to sub- 
ject R. B. are shown in Fig. 4. The relationships 
between the concentration of the different com- 
ponents are consistent with the results observed 
in a female mongrel dog .3 The highest concen- 
tration of penicillamine for any component was 
that in the plasma compartment. Throughout the 
time course during which penicillamine blood 
levels were measured most of the unchanged 
drug remained in the extracellular (plasma) 
compartment. The low intracellular levels (rel- 
ative to extracellular levels) are probably due to 
the intracellular presence of glutathione in red 
blood cells, which could readily oxidize the 
penicillamine transported inside these cells. 
The ratios of the plasma concentrations to the 
whole blood concentrations of penicillamine 
Volume 30 Penicillamine kinetics 409 
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Amount* 
Dose excreted Renal clearance 
Subjects (mg) (mg) % of closet (ml/min) 
R. B. 250 32.7 13.1 106 
500 83.7 16.7 95.9 
750 178 23.7 141 
750t 125 16.7 115 
750§ 56.3 7.5 101 
1,000 245 24.5 145 
D. F. 250 19.1 7.6 94.0 
500 30.2 6.0 114 
M. V. 250 32.1 12.8 69.6 
500 40.4 8.1 49.9 
750 74.7 10.0 62.9 
1,000 133 13.3 70.0 
C. M. 250 27.7 11.1 140 
500 55.7 11.1 71.5 
750 81.5 10.9 91.9 
750k 10.6 1.4 32.0 
1,000 117 11.7 88.7 
R. R. 250 7.5 3.0 70.1 
500 52.0 10.4 86.8 
750 88.2 11.8 81.0 
1,000 88.7 8.9 80.3 
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Table III. Calculated dose and body weight invariant -Kinetic parameters for the human 
kinetic study of penicillamine in five normal subjects 
were not consistent throughout the time course 
of the measured levels. The ratios gradually 
decreased with time so that relatively more of 
the penicillamine was found intracellularly in 
the later samples than in the early samples. 
However, the summation of the concentrations 
in the plasma and packed cells components 
when corrected for the hematocrit were (within 
analytic error) always equal to the concentration 
found in the whole blood. Since the whole 
blood levels of penicillamine reflect the con- 
centration in more than one compartment, 
plasma levels of penicillamine should be uti- 
lized for the study of the penicillamine kinetics. 
The use of the plasma levels has an additional 
advantage because the plasma concentrations 
Dose invariant AUC is the reciprocal of the body weight invariant apparent plasma clearance. 
*f = subject in fasting state; s = given in solution to subject in fasting state; b = given after large breakfast. 
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are higher than those found in the whole blood 
or packed cells. Thus, analytic determination of 
penicillamine in plasma is easier and the plasma 
levels can be observed for a longer period of 
time before the concentration falls below the 
limits of detection of the analytic methodology. 
Fig. 5 shows a comparison of the plasma 
levels of penicillamine for subject R. B. after a 
750-mg dose in capsules (fasting and after food) 
and as an oral solution (50 mg/ml) through a 
nasogastric tube). Unfortunately, difficulty was 
encountered during the administration of the 
oral solution when the connection between the 
nasogastric tube and the syringe containing the 
dose to be administered leaked. The dose was 
therefore less than 750 mg. Because the exact 
R. B. 
30 (M) 81.6 250 (f) 3.06 101 
500 (f) 6.13 142 
750 (f) 9.18 137 
1,000 (f) 12.2 138 
750 (s) 9.18 119 
750 (b) 9.18 60.9 
D. F. 
37 (M) 72.6 250 (f) 3.44 59.0 
500 (f) 6.89 38.3 
M. V. 
30 (F) 50.3 250 (f) 4.96 92.9 
500 (f) 9.93 81.6 
750 (f) 14.9 79.9 
1,000 (f) 19.9 95.0 
C. M. 
26 (F) 56.2 250 (f) 4.44 44.4 
500 (f) 8.89 87.6 
750 (f) 13.3 66.7 
1,000 (f) 17.8 74.1 
750 (s) 13.3 24.9 
750 (b) 
R. R. 
26 (M) 87.5 250 (f) 2.85 37.5 
500 (f) 5.71 105 
750 (f) 8.57 127 
1,000 (f) 11.4 96.8 
Dose invariant 
Treatment re- 
Subjects' Subjects' body ceived (mg peni- Dose A UC 
age and sex wt. (kg) cillamine)* (mg /kg) (mm/kg/1) 
Amount ex- 
creted in urine 
(mg /kg) 








magnitude of this error is not known a compari- 
son of the solution dose AUC to the AUCs of 
other doses is not valid. 
The relative shapes of the plasma concentra- 
tion-time profiles for these doses can, however, 
be compared. Both the oral solution dose and 
the capsule dose taken in the fasting state dis- 
play double peaks at approximately the same 
time after dose. These results suggest that the 
double peaks observed are not merely due to the 
administration of a number of capsules. 
The plasma levels of penicillamine resulting 
from the dose after a large breakfast showed a 
great reduction in the AUC and a disappearance 
of the double peaks. These observations were 
consistent in both subjects to whom doses were 
given after a large breakfast. 
Table I lists the kinetic parameters that were 
calculated based on the observed penicillamine 
plasma concentration data for the five subjects. 
The large apparent plasma clearances reported 
for subject D. F. are a reflection of the subject's 
poor absorption of the drug. Similarly, the large 
apparent plasma clearances reported for the 
doses given with food to subjects R. B. and 
C. M. are due to decreased absorption of un- 
changed penicillamine when it is taken after 
food. 
Urinary excretion of penicillamine. The in- 
trasubject variability in the plasma data was also 
observed in the urinary elimination of penicil- 
lamine. Table II lists the kinetic parameters for 
penicillamine that were calculated from the 
urine data for the five subjects. The percentages 
of the dose that were excreted unchanged 
ranged from 3% to 25% and the renal clearance 
of penicillamine ranged from 50 to 145 ml/min. 
The renal clearance of penicillamine reported 
in Table II was estimated as a ratio of the 
amount excreted in infinite time to the AUC 
from zero to infinite time. Excretion rates in the 
intervals 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 10, 
and 10 to 12 hr were also calculated and related 
to the plasma concentrations at the midpoints of 
the urinary excretion intervals, namely, 1, 3, 5, 
7, 9, and 11 hr. The data were pooled over dose 
for each subject and were plotted. The plots 
were linear for subjects R. B., D. F., M. U., 
and R. R., while the data for subject C. M. 
exhibited some curvature at the low plasma 
concentrations. The plot slopes are also esti- 
mates of the renal clearance. These renal clear- 
ances (104, 89.2, 64, and 80.2 ml/min for sub- 
jects R. B., D. F., M. U., and R. R., respec- 
tively) were of the same order as those reported 
in Table II. Their linearity suggests that penicil- 
lamine obeys a linear kinetic system and that it 
cannot be highly and tightly bound to plasma 
proteins. 
After two doses subject D. F. excreted less 
penicillamine in the urine than any of the other 
subjects at comparable doses. The renal excre- 
tion of penicillamine was also decreased in sub- 
jects R. B. and C. M. when the doses were 
taken with food. These reductions in the amount 
of drug excreted in are another reflection of the 
decreased absorption in these subjects. 
Invariant parameter analysis. To analyze 
10.7 9.9 1.30 
13.7 7.0 1.17 
19.4 7.3 1.73 
20.1 7.2 1.78 
13.6 8.4 1.41 
6.1 16.5 1.23 
5.55 16.9 1.29 
4.38 26.1 1.57 
6.47 10.8 1.38 
4.07 12.3 0.991 
5.01 12.6 1.25 
6.68 10.5 1.39 
6.24 22.5 2.49 
6.26 11.4 1.27 
6.13 15.0 1.63 
6.57 13.5 1.58 
0.80 40.3 0.57 
2.63 26.8 0.801 
9.11 9.53 0.991 
10.3 7.87 0.925 
7.78 10.3 0.917 
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the effect of dose and body weight on the ki- 
netic parameters of penicillamine, the parame- 
ters were calculated as dose invariant or body 
weight invariant. The results of these calcula- 
tions as well as the subject's age, sex, and body 
weight are shown in Table III. 
For the four fasting subjects the invariant pa- 
rameters were analyzed by a two-factor ANOVA 
for the effect of dose and subject. The dose 
invariant AUC was not different between doses 
(P < 0.05) but was different between subjects 
(P > 0.01). The dose invariant amount of pen- 
icillamine excreted in the urine and the body 
weight invariant renal clearance were also not 
different between doses (P < 0.1) but were dif- 
ferent between subjects (P > 0.025). The body 
weight invariant plasma clearance was not dif- 
ferent (P < 0.075) for either dose or subject. 
Discussion 
The atypical plasma concentration-time pat- 
terns in these studies are unusual. However, 
double peaks in the blood level curves have 
been observed for other drugs, including cimet- 
idine,4, 7, 9, 22-24 phenytoin,1°' 17 and phenol- 
phthalein .5 The occurrence of double peaks in 
our study of penicillamine does not appear to be 
merely due to the number of capsules taken be- 
cause a double peak was also observed for the 
subject given an oral solution. 
Other explanations for the occurrence of 
double peaks in the blood levels of drugs in- 
clude cyclic processes such as enterohepatic 
recirculation. In these cases, however, the 
double peak should be apparent regardless of 
the route of administration. The curves repre- 
senting intravenous penicillamine to a female 
mongrel dog3 did not exhibit double peaks, but 
the oral penicillamine in both man and dog did.3 
These results suggest that the occurrence of 
double peaks is linked to oral administration. 
(They were not evident, however, when the oral 
dose of penicillamine was administered after 
food.) 
Similar results have been described for cimet- 
idine.24 When this drug is administered intrave- 
nously, intramuscularly, or orally with food, 
double peaks are not observed but they are evi- 
dent after oral drug (without food). The causes 
of the double peaks observed for penicillamine 
Clin. Pharmacol. Ther. 
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and cimetidine have not been determined, but 
these unusual concentration-time profiles may 
be due to gastrointestinal transit time or an "ab- 
sorption window" effect. Vens Pedersen and 
Miller23' 24 theorized that the effects are due to a 
cyclic process that is interrupted by the presence 
of food and insignificant for the parenteral 
routes of administration. 
Our results have shown a significant decrease 
in the relative bioavailability of penicillamine 
when taken after a meal; bioavailability after 
food was only 44.4% and 37.3% of that when 
the subjects fasted. However, the apparent de- 
crease in absorption when the dose is taken after 
food must be interpreted with caution. Previous 
reports in our laboratory' have shown that 
penicillamine is readily oxidized (in vitro) to 
penicillamine disulfide when it is placed in the 
presence of proteinaceous material such as al- 
bumin. This oxidative process may also occur 
in the gastrointestinal tract when proteinaceous 
food materials are present (as egg albumin may 
have been in these studies). Since the analytic 
methodology used for the determination of pen- 
icillamine is specific for only the reduced form 
of penicillamine, the "complete" availability 
of the dose of (including both the reduced form 
and the disulfide or oxidized form) may be un- 
changed. A determination of both penicillamine 
and penicillamine disulfide was not obtained in 
this study. 
The therapeutically active modality for peni- 
cillamine in the treatment of rheumatoid arthri- 
tis is still unknown; so the reduction in the ab- 
sorption of the reduced form of penicillamine 
demonstrated by these studies may be of thera- 
peutic importance. Other studies are necessary 
to prove this relationship. 
The large intrasubject variability in the ki- 
netic parameters of penicillamine is of interest 
in light of the adverse effects in some individuals 
receiving long-term administration. A correla- 
tion of kinetic parameters such as renal clearance 
and dose invariant AUC with the occurrence of 
adverse effects such as proteinuria may be useful 
in elucidating the cause of the effects or in pre- 
dicting if they will occur. 
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